About: Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$8.01 (-1.84%)
CUVASXClinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Ltd share price
CUV price activity
Último preço
$ 8,010
Variação (24h)
-0,15 AUD (-1,84%)
Volume
178.09K
Volume (média 4 sem.)
-
Abertura
$ 8,17
Variação do dia
$ 7,95 - $ 8,26
Fechamento anterior
$ 8,16
Último negócio
10 Sep, 6:10 am GMT+0
Atrasado
10 Sep, 6:10 am GMT+0
CUV price performance
Atrasado
10 Sep, 6:10 am GMT+0
quote.marketSignals